Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Novartis Pharmaceuticals
Summary
The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Eligibility
- Age range
- 18–115 years
- Sex
- Male
- Healthy volunteers
- No
Inclusion criteria: * Evidence of 177Lu-PSMA-617 use on or after 01 January 2021. * Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617. * Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617. * Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617. * Age ≥18 years at index. Exclusion criteria: • None.
Location
- NovartisEast Hanover, New Jersey